Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Sheldon "Bud" Fantle

This article was originally published in The Tan Sheet

Executive Summary

Sheldon "Bud" Fantle: Former head of Peoples Drug Stores and Fantle's Drug Stores (formerly Dart) died Dec. 27 in Washington, D.C. of cancer. He was 73 and most recently had been a business consultant with Fantle Enterprises. Considered a giant of the chain drug industry, Fantle was known for turning Peoples around from a period of decline and, between 1975 and 1987, expanding the chain from 300 stores to more than 800 outlets with sales of nearly $1 bil. The National Association of Chain Drug Stores has named its highest honor in his memory, the Sheldon W. Fantle Lifetime Achievement Honor Award. In lieu of flowers, the Fantle family asks that contributions be made to the Washington Hospital Center Foundation, 100 Irving St., N.W., Washington, D.C. 20010...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel